share_log

Inhibikase Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-FiveT Investment Management Ltd(4.78%),FiveT Capital AG(4.78%)

Inhibikase Therapeutics | SC 13D:超過5%持股股東披露文件-FiveT Investment Management Ltd(4.78%),FiveT Capital AG(4.78%)

2023/02/24 12:27
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息